LIXIL-CORPORATION
2.7.2014 11:27:40 CEST | Business Wire | Pressemeddelelse
LIXIL Corporation (Headquarters: Chiyoda-ku, Tokyo; President: Yoshiaki Fujimori), a global leader in the housing products and building materials industry, and GROHE Group S.à r.l. (Headquarters: Luxembourg; CEO and Chairman: David Haines), LIXIL-affiliate company, today announced that they had agreed to acquire, via a newly established joint venture, 51% of the shares of watertech and sanitaryware clusters of Distribution & Warehousing Network Limited (Headquarters: Johannesburg, South Africa; President: Derek Tod; hereinafter “DAWN”). The acquisition based on this agreement is expected to be completed in autumn 2014.
DAWN’s watertech and sanitaryware clusters have annual gross sales of about 110 million euros (about 15.4 billion JPY, 1 euro =140 JPY) attaining a growth rate of about 10% last fiscal year, and it holds a major share of South Africa’s watertech and sanitaryware market.
The joint venture agreement will make LIXIL one of the leading suppliers of sanitary fittings in South Africa. GROHE gains production facilities in South Africa and will further expand its distribution network and strengthen business activities in Africa.
Yoshiaki Fujimori, President and CEO of LIXIL, 43.75% owner of GROHE said "Expansion in emerging markets, especially Africa, is consistent with the strategy of LIXIL Group".
The LIXIL Group declared its goal of “becoming a comprehensive housing solutions provider targeting the global market” in its Medium-term Management Vision announced in May 2011, and it has been expanding its business to achieve growth and expansion on a global scale. This transaction opens the way for GROHE to successfully continue its long-term growth strategy with partner LIXIL at its side.
About Distribution & Warehousing Network Limited
DAWN is listed in Johannesburg Stock Exchange (JSE). The Group manufactures and distributes quality branded hardware, sanitaryware, plumbing, kitchen, engineering and civil products through a national, strategically positioned branch network in South Africa, as well as in selected countries in the rest of Africa and Mauritius. The brands acquired through the new agreement include COBRA, ISCA, VAAL, LIBRA and PLEXICOR. For more information, please visit: http://www.dawnltd.co.za/
About GROHE Group S.à r.l.
GROHE is one of the world’s leading providers of sanitary fittings operating over 130 countries. Under the global GROHE brand for sanitary products and systems, GROHE sets a high standard in quality, design, technology and responsibility, providing water to perfection. With the Joyou brand, the GROHE Group covers the fast growing Chinese market. Staffed by about 9,300 employees, it offers brands differing by price range and design: GROHE®, GROHE Professional®, GROHE SPA®, and Joyou®. Both companies became equity method affiliate companies of the LIXIL Group as a result of the January 2014 joint acquisition of 87.5% of GROHE’s shares by the LIXIL Group and the Development Bank of Japan.
For more information, please visit: http://www.grohe.com/
About LIXIL Corporation
Led by President and CEO Yoshiaki Fujimori, LIXIL Group Corporation (TSE Code: 5938) is a listed holding company posting 1.6 trillion JPY in consolidated sales in FY March 2014. The Group is involved in a broad spectrum of housing-related businesses, ranging from the manufacture and sales of building materials and housing equipment to the operation of home centers and a network of homebuilding franchises.
LIXIL Corporation, a consortium of building material companies, is a core enterprise of the Group, generating 80% of consolidated sales. The largest housing and building materials company in Japan with a vast and unique business portfolio, a 55% share in exteriors, 50% share in housing sashes and doors, 50% share in building sashes and shutters and 40% share in sanitary ware. LIXIL is also a leading brand such as in tiles, unit bathrooms and kitchen systems.
Launched in April 2011 under its present structure and name, LIXIL has been active in strategic acquisitions and partnerships in order to fortify and accelerate its growth globally. It currently operates in more than 30 countries through various brands offering a broad lineup of products and services. Permasteelisa, Gartner and Shanghai Meite, for example, spearhead our project business (building materials and curtain wall), while LIXIL, American Standard, Inax and Tostem brands provide an impressive product portfolio including kitchen units, bathroom fixtures, windows and doors.
For more information about LIXIL Group, please visit: http://www.lixil-group.co.jp/e/
Contact:
Media Contact
LIXIL Group Corporation
Miyuki Otomo, +81
3 6268 8801
Corporate Communication Division
otomom1@lixil.co.jp
Link:
Information om Business Wire
Følg pressemeddelelser fra Business Wire
Skriv dig op her, og modtag pressemeddelelser på e-mail. Indtast din e-mail, klik på abonner, og følg instruktionerne i den udsendte e-mail.
Flere pressemeddelelser fra Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter samt finde vores kontaktoplysninger.
Besøg vores nyhedsrum
